94084-76-1

Basic information

• Product Name: 6-(benzyloxy)nicotinic acid
• Synonyms: 6-(benzyloxy)nicotinic acid
• CAS NO: 94084-76-1
• Molecular Formula: C12H11NO3
• Molecular Weight: 229
• Product Categories: Carboxylic Acids;Carboxylic Acids;Pyridines
• Mol File: 94084-76-1.mol

Chemical Properties

• Boiling Point: 400.3°C at 760 mmHg
• Flash Point: 195.9°C
• Appearance: /
• Density: 1.274g/cm³
• Vapor Pressure: 3.99E-07mmHg at 25°C
• Refractive Index: 1.61
• CAS DataBase Reference: 6-(benzyloxy)nicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(benzyloxy)nicotinic acid(94084-76-1)
• EPA Substance Registry System: 6-(benzyloxy)nicotinic acid(94084-76-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 94084-76-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-(benzyloxy)nicotinic acid is utilized as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its role in drug creation is multifaceted, as it aids in the production of a diverse range of medicinal compounds.
Used in Agrochemical Production:
In the agrochemical sector, 6-(benzyloxy)nicotinic acid serves as a precursor in the formulation of various chemical substances. Its application in this industry is instrumental in creating products that protect crops and enhance agricultural productivity.
Used in Chemical Substances Production:
Beyond its pharmaceutical and agrochemical applications, 6-(benzyloxy)nicotinic acid is also employed as a precursor in the production of a wide array of other chemical substances. Its versatility in chemical synthesis makes it an indispensable component in various industrial processes.
Used in Antioxidant and Anti-Inflammatory Agents Development:
Leveraging its inherent antioxidant and anti-inflammatory properties, 6-(benzyloxy)nicotinic acid is explored for its potential in the development of new therapeutic agents. Its capacity to combat oxidative stress and inflammation positions it as a valuable asset in the creation of innovative treatments for a variety of conditions.

InChI:InChI=1/C13H11NO3/c15-13(16)11-6-7-12(14-8-11)17-9-10-4-2-1-3-5-10/h1-8H,9H2,(H,15,16)

Upstream product

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 100-51-6 benzyl alcohol 
• 83664-33-9 2-(benzyloxy)-5-bromopyridine 
• 124-38-9 carbon dioxide 
• 33252-28-7 6-chloronicotinonitrile 
• 151028-49-8 methyl 6-(benzyloxy)nicotinate 
• 66171-50-4 methyl 6-hydroxynicotinate 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 876516-71-1 6-(benzyloxy)nicotinonitrile 

Relevant articles and documents

First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump

Overexpression of efflux pumps is an important mechanism of bacterial resistance that results in the extrusion of antimicrobial agents outside the bacterial cell. Inhibition of such pumps appears to be a promising strategy that could restore the potency of existing antibiotics. The NorA efflux pump of Staphylococcus aureus confers resistance to a wide range of unrelated substrates, such as hydrophilic fluoroquinolones, leading to a multidrug-resistance phenotype. In this work, approximately 150 heterocyclic boronic species were evaluated for their activity against susceptible and resistant strains of S. aureus. Twenty-four hit compounds, although inactive when tested alone, were found to potentiate ciprofloxacin activity by a 4-fold increase at concentrations ranging from 0.5 to 8 μg/mL against S. aureus 1199B, which overexpresses NorA. Boron-free analogues showed no biological activity, thus revealing that the boron atom is crucial for biological activity. This work describes the first reported efflux pump inhibitory activity of boronic acid derivatives.

Neonicotinic analogues: Selective antagonists for α4β2 nicotinic acetylcholine receptors

Nicotine is an agonist of nicotinic acetylcholine receptors (nAChRs) that has been extensively used as a template for the synthesis of α4β2-preferring nAChRs. Here, we used the N-methyl-pyrrolidine moiety of nicotine to design and synthesise novel α4β2-preferring neonicotinic ligands. We increased the distance between the basic nitrogen and aromatic group of nicotine by introducing an ester functionality that also mimics acetylcholine (Fig. 2). Additionally, we introduced a benzyloxy group linked to the benzoyl moiety. Although the neonicotinic compounds fully inhibited binding of both [α-125I]bungarotoxin to human α7 nAChRs and [3H]cytisine to human α4β2 nAChRs, they were markedly more potent at displacing radioligand binding to human α4β2 nAChRs than to α7 nAChRs. Functional assays showed that the neonicotinic compounds behave as antagonists at α4β2 and α4β2α5 nAChRs. Substitutions on the aromatic ring of the compounds produced compounds that displayed marked selectivity for α4β2 or α4β2α5 nAChRs. Docking of the compounds on homology models of the agonist binding site at the α4/β2 subunit interfaces of α4β2 nAChRs suggested the compounds inhibit function of this nAChR type by binding the agonist binding site.

PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS

Disclosed are compounds of formula (I) and compositions of the present invention which are inhibitors of the sodium proton exchanger isoform-1 (NHE-I). Also disclosed are methods of using and making the same.

New H-bonded complexes and their supramolecular liquid-crystalline organizations

Different approaches to the design of liquid crystals by using H-bonds were analyzed. A selection of stilbazoles and pyridine compounds, with one or two chelating positions, were used as H-acceptors in mixtures with carboxylic acids. The noncovalent compl

Pyridine amido derivatives

Disclosed are pyridine amido derivatives of the formula wherein X, Y, and R1 to R6 are as defined herein. These compounds are selective MAO-B inhibitors and are useful in treating diseases such as, for example, Alzheimer's and senile dementia. Also disclosed are pharmaceutical compositions containing such compounds and a method of preparing such compounds.

Ferroelectric liquid crystals with nicotinic acid cores

Liquid crystal and ferroelectric liquid crystal compounds having core moieties based on nicotinic acid and having the general formula: STR1 where A is N or N--O and where R1 and R2, independently of one another, are straight chain or branched alkyl groups having from 1 to 20 carbons are provided. Ferroelectric liquid crystals of the present invention include those compounds in which one of R1 or R2 are chiral nonracemic groups. The pyridines and pyridine n-oxides or the present invention are useful as components of liquid crystal materials and certain of these compounds are useful as components of ferroelectric liquid crystal materials.